| 1 |
Tian G, Wang W, Xia E, Chen W, Zhang S. Dendrobium officinale alleviates high-fat diet-induced nonalcoholic steatohepatitis by modulating gut microbiota. Front Cell Infect Microbiol 2023;13:1078447. [PMID: 36860985 DOI: 10.3389/fcimb.2023.1078447] [Reference Citation Analysis]
|
| 2 |
Chang D, Truong E, Mena EA, Pacheco F, Wong M, Guindi M, Todo TT, Noureddin N, Ayoub W, Yang JD, Kim IK, Kohli A, Alkhouri N, Harrison S, Noureddin M. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. Hepatology 2023;77:546-57. [PMID: 35809234 DOI: 10.1002/hep.32655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Cholankeril G, El-Serag HB. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2023;43:89-99. [PMID: 36216350 DOI: 10.1055/a-1957-8540] [Reference Citation Analysis]
|
| 4 |
Atic AI, Thiele M, Munk A, Dalgaard LT. Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 2023;324:C588-602. [PMID: 36645666 DOI: 10.1152/ajpcell.00253.2022] [Reference Citation Analysis]
|
| 5 |
Liao Y, Wang L, Liu F, Zhou Y, Lin X, Zhao Z, Xu S, Tang D, Jiao Y, Yang L, Yu W, Gao P. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. Front Endocrinol (Lausanne) 2023;14:1078149. [PMID: 36761200 DOI: 10.3389/fendo.2023.1078149] [Reference Citation Analysis]
|
| 6 |
Zhi G, Shao B, Zheng T, Mu J, Li J, Feng Y, Zhu S, Dang Y, Liu F, Wang D. Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification. Front Pharmacol 2023;14:1082451. [PMID: 36762105 DOI: 10.3389/fphar.2023.1082451] [Reference Citation Analysis]
|
| 7 |
Lv S, Zhang Z, Su X, Li W, Wang X, Pan B, Li H, Zhang H, Wang Y. Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway. Front Endocrinol (Lausanne) 2022;13:1106875. [PMID: 36743916 DOI: 10.3389/fendo.2022.1106875] [Reference Citation Analysis]
|
| 8 |
Wang D, Xu Y, Zhu Z, Li Y, Li X, Li Y, Shen H, Wu W, Liu Y, Han C. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. Front Nutr 2022;9:1047129. [PMID: 36618688 DOI: 10.3389/fnut.2022.1047129] [Reference Citation Analysis]
|
| 9 |
Chen S, Tang L, Guillot A, Liu H. Bariatric Surgery Associates with Nonalcoholic Steatohepatitis/Hepatocellular Carcinoma Amelioration via SPP1 Suppression. Metabolites 2022;13. [PMID: 36676937 DOI: 10.3390/metabo13010011] [Reference Citation Analysis]
|
| 10 |
Frohlich J, Raffaele M, Skalova H, Leire E, Pata I, Pata P, Gorbunova V, Vinciguerra M. Human centenarian-associated SIRT6 mutants modulate hepatocyte metabolism and collagen deposition in multilineage hepatic 3D spheroids. Geroscience 2023;45:1177-96. [PMID: 36534275 DOI: 10.1007/s11357-022-00713-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Stachowska E, Maciejewska-Markiewicz D, Palma J, Mielko KA, Qasem B, Kozłowska-Petriczko K, Ufnal M, Sokolowska KE, Hawryłkowicz V, Załęska P, Jakubczyk K, Wunsch E, Ryterska K, Skonieczna-Żydecka K, Młynarz P. Precision Nutrition in NAFLD: Effects of a High-Fiber Intervention on the Serum Metabolome of NAFD Patients-A Pilot Study. Nutrients 2022;14. [PMID: 36558512 DOI: 10.3390/nu14245355] [Reference Citation Analysis]
|
| 12 |
Wang Y, Lu S, Gui R, Wu J, Li J, He X, Zhang W, Deng G, Wang W, Long H, Wei X, Zeng G, Zhang N, Zang S, Yao Y, Chen Z, Fei C, Wang Y, Xu K. Hepatic lipidomics and proteomics analysis reveals the mechanism of Cyclocarya paliurus flavonoids in preventing non-alcoholic steatohepatitis in mice. Journal of Functional Foods 2022;99:105341. [DOI: 10.1016/j.jff.2022.105341] [Reference Citation Analysis]
|
| 13 |
Sempokuya T, Warner J, Azawi M, Nogimura A, Wong LL. Current status of disparity in liver disease. World J Hepatol 2022;14:1940-52. [PMID: 36483604 DOI: 10.4254/wjh.v14.i11.1940] [Reference Citation Analysis]
|
| 14 |
Unalp-Arida A, Ruhl CE. Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States. Dig Dis Sci 2022;:1-16. [PMID: 36173583 DOI: 10.1007/s10620-022-07707-1] [Reference Citation Analysis]
|
| 15 |
Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology 2022;163:764-774.e1. [PMID: 35842345 DOI: 10.1053/j.gastro.2022.06.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 16 |
Meneghel P, Pinto E, Russo FP. Physiopathology of nonalcoholic fatty liver disease: from diet to nutrigenomics. Curr Opin Clin Nutr Metab Care 2022;25:329-33. [PMID: 35920204 DOI: 10.1097/MCO.0000000000000859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 17 |
Liu Y, Li Y, Wang J, Yang L, Yu X, Huang P, Song H, Zheng P. Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway. BMC Complement Med Ther 2022;22:213. [DOI: 10.1186/s12906-022-03697-9] [Reference Citation Analysis]
|
| 18 |
Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, Ribaldone DG, Fermer C, Saracco GM, Gaia S, Bugianesi E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Curr Oncol 2022;29:5457-65. [PMID: 36005169 DOI: 10.3390/curroncol29080431] [Reference Citation Analysis]
|
| 19 |
Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02410-x] [Reference Citation Analysis]
|
| 20 |
Novo E, Cappon A, Villano G, Quarta S, Cannito S, Bocca C, Turato C, Guido M, Maggiora M, Protopapa F, Sutti S, Provera A, Ruvoletto M, Biasiolo A, Foglia B, Albano E, Pontisso P, Parola M. SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease. Front Immunol 2022;13:910526. [DOI: 10.3389/fimmu.2022.910526] [Reference Citation Analysis]
|
| 21 |
Kanwal F, Shubrook JH, Cusi K. Reply. Gastroenterology 2022;162:2132-4. [PMID: 35183548 DOI: 10.1053/j.gastro.2022.02.019] [Reference Citation Analysis]
|
| 22 |
Blériot C, Ginhoux F. Une sous-population de macrophages hépatiques impliquée dans la régulation du métabolisme. Med Sci (Paris) 2022;38:532-536. [DOI: 10.1051/medsci/2022070] [Reference Citation Analysis]
|
| 23 |
Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 24 |
Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 25 |
Unalp-arida A, Ruhl CE. Prepandemic prevalence estimates of fatty liver disease and fibrosis defined by liver elastography in the United States.. [DOI: 10.1101/2022.04.05.22273458] [Reference Citation Analysis]
|
| 26 |
Angelidi AM, Papadaki A, Nolen-Doerr E, Boutari C, Mantzoros CS. The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials. Metabolism 2022;:155136. [PMID: 35032545 DOI: 10.1016/j.metabol.2022.155136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 27 |
Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab 2022;107:29-38. [PMID: 34406410 DOI: 10.1210/clinem/dgab578] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 28 |
Alexopoulos AS, Duffy R, Kobe EA, German J, Moylan CA, Soliman D, Jeffreys AS, Coffman CJ, Crowley MJ. Underrecognition of Nonalcoholic Fatty Liver Disease in Poorly Controlled Diabetes: A Call to Action in Diabetes Care. J Endocr Soc 2021;5:bvab155. [PMID: 34755002 DOI: 10.1210/jendso/bvab155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 29 |
Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021;161:1657-69. [PMID: 34602251 DOI: 10.1053/j.gastro.2021.07.049] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 43.5] [Reference Citation Analysis]
|
